Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 14/20 | 0.49 |
| ▸ | RAB9A | P51151 | 14/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 13/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.49 |
| ▸ | RELA | Q04206 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5803954 | 1.00 | NPC1 (0.49) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL5804543 | 0.81 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL5801266 | 0.81 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL31171044 | 0.77 | NPC1 (0.75) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL4826876 | 0.76 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2LMNAMEN1 | |
| SCHEMBL1747973 | 0.74 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2LMNANFKB1 | |
| SCHEMBL732658 | 0.73 | SNCA (0.58) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL14882238 | 0.73 | MAPT (0.60) | NPC1RAB9ASMN1; SMN2LMNAMEN1 | |
| SCHEMBL18230156 | 0.72 | SNCA (0.42) | SNCAIDO1ADORA1 | |
| SCHEMBL1621585 | 0.72 | SNCA (0.50) | NPC1RAB9ASMN1; SMN2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385524-A4 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO KG (DE) | 2006-02-01 | — | — | EP | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| EP-1385524-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | Abbott GmbH & Co. KG (DE) | 2004-02-04 | — | — | EP | disclosed |
| US-6660744-B1 | Kinase inhibitors | ABBOTT GMBH & CO. KG (DE) | 2003-12-09 | — | — | US | disclosed |
| EP-1212327-B1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | BASF AG (DE) | 2003-08-20 | — | — | EP | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
| WO-2002080926-A1 | PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS | ABBOTT GMBH & CO. KG (DE) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | NPC1 991/4885RAB9A 975/4885SMN1; SMN2 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.